ClinicalTrials.gg
CompletedNCT03476499Updated Apr 13, 2021

Near Infrared Imaging and Flap Necrosis

An interventional study of Near Infrared Imaging (NIR) device in Flap Necrosis, sponsored by University Health Network, Toronto. Completed at 2 sites in Canada. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-13.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Sex
Female
01

Study summary

Skin flaps following mastectomy breast surgery that do not have enough oxygen are at risk for necrosis which can increase wound healing problems, postoperative recovery time and be costly to the hospital systems and affect the patient quality of life, poor esthetic results and overall reconstructive success. Mastectomy skin flap necrosis (MSFN) has an incidence of 10-15% with higher rates (7% - 30%) in mastectomy procedures with immediate reconstruction. Intraoperative assessment of the circulation in skin flaps is currently done with clinical assessment tools utilizing somewhat subjective identifiers such as flap color, capillary refill, temperature and dermal edge bleeding to determine the viability of the flap. Several technologies have been developed to assist in the clinical judgement of skin flaps but these technologies are not yet widely used because of the cost of the technology, the time required to image the patient, the intravenous injection of indocyanine green (ICG) dye required for contrast and the inability to image repeatedly and in different environments (pre-op, intra-op and post-op). A new commercially available imaging technology uses NIR spectroscopy to measure regional tissue hemoglobin oxygenation, using images that are taken 12 inches away from the patient. Preclinical data shows that NIR can predict necrosis in flaps but clinical data is needed to characterize and assess the value of the technology in plastic and reconstructive surgery. The purpose of this research study is to explore the ability of NIR imaging to predict skin flap tissue viability in the clinical setting of immediate breast reconstruction procedures. Study Design: This is a prospective, non-interventional study that will explore the ability of NIR imaging to predict of tissue viability in immediate breast reconstruction procedures. Necrosis will be scored using the SKIN score. Participation in the study will not impact patient care; all patients will receive standard care.

Read the detailed description

Background of the study:

There are commercial medical devices that measure the spectrum of near infrared light reflected from at a single location of tissue. These non-imaging devices are also called point NIR spectroscopy devices. Point NIR spectroscopy devices have been used to monitor blood perfusion to free flaps and mastectomy flaps. The unit of measurement is StO2; StO2 is a measure of hemoglobin oxygen saturation weighted towards the saturation in the microvascular bed as opposed to SaO2 or SvO2 which correspond to the arterial and venous hemoglobin saturation respectively. StO2 is mixed arterial - venous measure of hemoglobin oxygen saturation. Point devices use a light delivery and collection probe that needs to be in contact with tissue. They can measure on the order of \~10mm deep over an area of approximately 1cm by 1cm depending on the configuration of the device. Some studies using point devices have shown significant differences in StO2 values in flaps that became necrotic versus flaps that remained viable. NIR point systems however are not widely used intraoperatively because they need to be brought in contact with the tissue being measured. They also measure small areas thereby necessitating measurements over many spatially distinct points on the flap to get a comprehensive measurement of flap oxygenation.

Rationale for this study A new commercially available imaging technology uses NIR spectroscopy to measure regional tissue hemoglobin oxygenation, StO2. The device is based on the same principles as point NIR spectroscopy devices but instead of contacting the skin a set of images are taken 12 inches away from the patient. These images are processed to produce a colour coded StO2 image of a large tissue area (\~6" by 4"). Since the image device doesn't contact the skin the depth of measurement is \~2mm instead of \~10mm with a point system. Compared to dye based angiography methods, StO2 NIR imaging does not require the injection of a dye. The advantage of the NIR imaging device over point NIR systems is a lack of patient contact. Thus StO2 NIR imaging is completely non-invasive, non-contact. Images can be captured and displayed in less than 5 seconds therefore imaging can be repeated as needed with no risk to the patient and no cost for disposables. Preclinical data shows that NIR can predict necrosis in flaps but clinical data is needed to characterize and assess the value of the technology in plastic and reconstructive surgery.

Study hypotheses or research questions This study will explore the ability of NIR imaging to predict of tissue viability in immediate breast reconstruction procedures. Necrosis will be scored using the SKIN score.

Primary objectives and secondary objectives:

Aim 1: To establish the NIR parameters that are consistent with flap viability. Aim 1: To develop parameters to predict flap viability intraoperatively. Aim 3: To determine if NIR values correspond to SKIN scores

Significance of the study The Innovation is a non-contact, non-invasive means to map/image the oxygen available to an area of tissue. It requires no setup time and there are no consumables associated with its measurement method. As cellular respiration in tissue requires an adequate supply of oxygen, the tissue hemoglobin oxygen saturation image provided by the Innovation can detect areas of tissue that are threatened by a poor oxygen supply. The oxygenation measures provided by the device give surgeons insight into the healing potential of skin flaps in procedures such as mastectomies. Skin flaps that are not sufficiently oxygenated are at risk for necrosis which can be costly to the hospital systems and affect the patient quality of life. The Innovation's oxygenation image assists surgeons in identifying areas of flap ischemia intra-operatively and can be used to monitor flaps post-operatively. With early identification of ischemic areas surgeons can intervene earlier to reduce the risk of flap necrosis.

02

Conditions studied

  • Flap Necrosis

Browse trials for

03

In context

Necrosis

90 studies on the registry are indexed under Necrosis; 23 are open to participants now.

This study's enrollment of 101 is above the median of 50 across 53 interventional studies indexed under Necrosis.

Browse Necrosis studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,438 studies on the registry; 297 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • i. Planned skin flap procedure
  • ii. SpO2 above 96%
  • iii: Written .

Exclusion criteria

Exclusion Criteria:

  • Use of epinephrine, patent blue V or methelyne blue during procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Planned skin flap procedure

    Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent. Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure. The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care. The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging. * One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery. * One set of intra-operative Images that will be taken intra-operatively following the mastectomy. * One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care.

    Device: Near Infrared Imaging (NIR) device

Interventions

  • DeviceNear Infrared Imaging (NIR) device

    Handheld near infrared multispectral imaging device with custom software.

    Also known as: KENT CAMERA MULTISPECTRAL IMAGING DEVICE

06

What researchers measure

Primary outcomes

  1. Extent of mastectomy skin flap necrosis

    Partial/superficial necrosis and full-thickness necrosis as quantified by a SKIN score. These areas will be correlated with the intraoperative StO2 values from the NIR images.

    Time frame: 1 month

Secondary outcomes

  1. Infection

    Superficial, deep or organ space surgical site infection. Patients treated with oral or IV antibiotics will be documented, including patients who have loss of implant due to infection.

    Time frame: 1 month

  2. Wound Dehiscence or Implant Extrusion

    Wound breakdown and/or exposure of implant will be documented.

    Time frame: 1 month

  3. Seroma/Hematoma

    Any evidence of seroma /hematoma will be documented as will any surgical intervention or observation.

    Time frame: 1 month

  4. Removal or Loss of Implant

    Patients who require removal of their implants will be documented along with the reason for removal of implant.

    Time frame: 1 month

07

Study locations

2 sites
  • Sinai Health System
    Toronto, Ontario M5G 1X5, Canada
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jan 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Mar 26, 2018
StartActual
Oct 29, 2018
Primary completionActual
Jan 31, 2020
CompletionActual
Feb 29, 2020
Last update
Apr 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03476499
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Oct 29, 2018
Primary completion
Jan 31, 2020
Completion
Feb 29, 2020
Last update
Apr 13, 2021

Study contacts

Stefan OP Hofer, PhD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion